is a topic covered in the Johns Hopkins ABX Guide
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
- Two different brand names were FDA approved in 2018
- Krintafel™- Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
- Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
- Arakoda™-prophylaxis of malaria in patients ≥18 years of age
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: January 2, 2019
Avdic, Edina. "Tafenoquine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine.
Avdic E. Tafenoquine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine. Accessed October 20, 2019.
Avdic, E. (2019). Tafenoquine. In Johns Hopkins ABX Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine
Avdic E. Tafenoquine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2019 October 20]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine.
TY - ELEC
T1 - Tafenoquine
ID - 540701
A1 - Avdic,Edina,Pharm.D.
Y1 - 2019/01/02/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine